Paragonix in the News

News & External Coverage of Paragonix®

Watch news coverage of Paragonix® products and learn more about why transplant centers are implementing Paragonix SherpaPak™ Cardiac Transport System into their donor heart transport program. Please review the Indications of Use of Paragonix SherpaPak™ Cardiac Transport System below.

Paragonix Sponsors Hiking Expedition For Recent Lung Transplant Recipients

Paragonix is immensely proud to sponsor one of the most amazing sporting events of 2019: an expedition of a group of 50 patients and medical professionals to the highest mountain of North Africa, Jebel Toubkal (4200m). What’s so incredible about these patients? They have reached the peak of Jebel Toubkal breathing with new lungs! The international group consisted of  lung transplant recipients from Austria, Germany, Hungary, Italy, Greece and Romania.

Supported by the amazing medical teams of the Medical University of Vienna and the Medical University of Essen, this trek was not just to achieve the almost impossible, but to gain deep scientific understanding of the impact of high altitude on lung transplant recipients. During the trek, regular measurements of heart function, lung function as well as blood gas analyses were performed.

The research is funded by Lunge Aktiv. Please join us in congratulating the group for this accomplishment!




Paragonix Gets FDA Nod for Pediatric Heart Transport Device December 20, 2018 The Braintree, MA-based firm’s Paragonix SherpaPak Cardiac Transport System also has clearance for the adult patient population.

Read more


FDA clears Paragonix’s pediatric donor heart transport system Jan 7, 2019 The FDA has cleared a new insulated organ transport system designed for shepherding small and pediatric hearts from donors to transplant recipients.

Read more



SherpaPak Cardiac Transport System Cleared for Pediatric and Small Donor Hearts February 01, 2019 System will be shipped with heart connectors covering most aortic diameters beginning Q1 2019

Read more

Indications of Use: The Paragonix SherpaPak™ Cardiac Transport System is intended to be used for the static hypothermic preservation of hearts during transportation and eventual transplantation into a recipient using cold storage solutions indicated for use with the heart. The intended organ storage time for the Paragonix SherpaPak™ Cardiac Transport System is up to 4 hours. Donor hearts exceeding clinically accepted static hypothermic preservation times should be evaluated by the transplant surgeon to determine transplantability in accordance with accepted clinical guidelines and in the best medical interest of the intended recipient. Please review the instructions for use for complete prescribing information including indications, contraindications, warnings and precautions.